Impact of parathyroidectomy on serum FGF23 and soluble klotho in hemodialysis patients with severe secondary hyperparathyroidism

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 4, 2014, Pages

  Takahashi, Hiroo ^a   Komaba, Hirotaka ^a   Takahashi, Yuichiro ^b   Sawada, Kaichiro ^a   Tatsumi, Ryoko ^a   Kanai, Genta ^a   Suzuki, Hajime ^c   Kakuta, Takatoshi ^a   Fukagawa, Masafumi ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Jinken Clinic   (Japan)

^c TOKAI UNIVERSITY OISO HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CINACALCET; FIBROBLAST GROWTH FACTOR 23; KLOTHO PROTEIN; PARATHYROID HORMONE; PHOSPHATE;

ADULT; ARTICLE; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; FEMALE; HEMODIALYSIS PATIENT; HUMAN; MALE; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROIDECTOMY; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SECONDARY HYPERPARATHYROIDISM;

AGED; FEMALE; FIBROBLAST GROWTH FACTORS; GLUCURONIDASE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NAPHTHALENES; PARATHYROIDECTOMY; POSTOPERATIVE PERIOD; RENAL DIALYSIS; SEVERITY OF ILLNESS INDEX; SOLUBILITY;

EID: 84898465695     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-4050     Document Type: Article

References (26)

1. Komaba H, Fukagawa M. The role of FGF23 in CKD-with or without Klotho. Nat Rev Nephrol . 2012;8:484-490.
2. Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004;19:429-435.
3. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest . 2007;117:4003-4008.
4. Kuro-o M, Matsumura Y, Aizawa H, et al. Mutation of the mouse Klotho gene leads to a syndrome resembling ageing. Nature . 1997; 390:45-51.
5. Urakawa I, Yamazaki Y, Shimada T, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature . 2006; 444:770-774.
6. Chang Q, Hoefs S, van der Kemp AW, Topala CN, Bindels RJ, Hoenderop JG. The -glucuronidase klotho hydrolyzes and activates the TRPV5 channel. Science . 2005;310:490-493.
7. Hu MC, Shi M, Zhang J, et al. Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule. FASEB J . 2010;24:3438-3450.
8. Tominaga Y, Numano M, Tanaka Y, Uchida K, Takagi H. Surgical treatment of renal hyperparathyroidism. Semin Surg Oncol . 1997; 13:87-96.
9. Hu MC, Shi M, Zhang J, et al. Klotho deficiency causes vascular calcification in chronic kidney disease. J AmSoc Nephrol . 2011;22: 124-136.
10. Xie J, Cha SK, An SW, Kuro-o M, Birnbaumer L, Huang CL. Cardioprotection by Klotho through downregulation of TRPC6 channels in the mouse heart. Nat Commun . 2012;3:1238.
11. Koizumi M, Komaba H, Nakanishi S, Fujimori A, Fukagawa M. Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism. Nephrol Dial Transplant . 2012;27:784-790.
12. Komaba H, Koizumi M, Tanaka H, et al. Effects of cinacalcet treatment on serum soluble Klotho levels in haemodialysis patients with secondary hyperparathyroidism. Nephrol Dial Transplant . 2012; 27:1967-1969.
13. Fukagawa M, Yokoyama K, Koiwa F, et al. Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. Ther Apher Dial . 2013;17:247-288.
14. Shimizu Y, Fukumoto S, Fujita T. Evaluation of a new automated chemiluminescence immunoassay for FGF23. J Bone Miner Metab . 2012;30:217-221.
15. Yamazaki Y, Imura A, Urakawa I, et al. Establishment of sandwich ELISA for soluble -klotho measurement: age-dependent change of soluble -klotho levels in healthy subjects. Biochem Biophys Res Commun . 2010;398:513-518.
16. Komaba H, Nakanishi S, Fujimori A, et al. Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism. Clin J Am Soc Nephrol . 2010;5:2305-2314.
17. Komaba H, Goto S, Fujii H, et al. Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int . 2010;77:232-238.
18. Sato T, Tominaga Y, Ueki T, et al. Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism. Am J Kidney Dis . 2004;44:481-487.
19. Lau WL, Leaf EM, Hu MC, et al. Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet. Kidney Int . 2012;82:1261-1270.
20. Bleyer AJ, Burkart J, Piazza M, Russell G, Rohr M, Carr JJ. Changes in cardiovascular calcification after parathyroidectomy in patients with ESRD. Am J Kidney Dis . 2005;46:464-469.
21. Dreke T, FauchetM,Fleury J, et al. Effect of parathyroidectomy on left-ventricular function in haemodialysis patients. Lancet . 1980;1: 112-114.
22. Kestenbaum B, Andress DL, Schwartz SM, et al. Survival following parathyroidectomy among United States dialysis patients. Kidney Int . 2004;66:2010-2016.
23. Smith RC, OBryan LM, Farrow EG, et al. Circulating -Klotho influences phosphate handling by controlling FGF23 production. J Clin Invest . 2012;122:4710-4715.
24. Liu S, Tang W, Zhou J, et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol . 2006;17:1305-1315.
25. Lavi-Moshayoff V, Wasserman G, Meir T, Silver J, Naveh-Many T. PTHincreasesFGF23gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol . 2010;299:F882-F889.
26. Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest . 2011;121:4393-4408.